NCT00028002View on ClinicalTrials.gov

Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

January 28, 2009

Study Completion Date

January 28, 2009

Conditions
Gastrointestinal Stromal Tumor
Interventions
PROCEDURE

Conventional Surgery

Undergo surgical resection

DRUG

Imatinib Mesylate

Given orally

Trial Locations (1)

19103

Radiation Therapy Oncology Group, Philadelphia

All Listed Sponsors
collaborator

American College of Radiology Imaging Network

NETWORK

collaborator

Eastern Cooperative Oncology Group

NETWORK

collaborator

Radiation Therapy Oncology Group

NETWORK

lead

National Cancer Institute (NCI)

NIH

NCT00028002 - Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor | Biotech Hunter | Biotech Hunter